Biogen (BIIB) and Denali Therapeutics (DNLI) announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle:Amyloid beta program, ATV:ABeta. Accumulation of Abeta plaque in the brain is a defining feature of Alzheimer’s disease. Using Denali’s ATV platform to cross the blood-brain barrier, ATV:Abeta is designed to increase brain exposure and target engagement of antibody therapeutics directed against Abeta, which may enable improved plaque clearance and/or reduced amyloid-related imaging abnormalities . "Recent progress with Abeta-directed therapeutic antibodies enables new treatment options for people living with AD, and clinical trial data have demonstrated that clearance of aggregated Abeta is associated with benefit for patients," said Joseph Lewcock, Ph.D., Chief Scientific Officer of Denali. "Our ATV:Abeta program is designed to safely increase exposure of the therapeutic antibody in the brain and potentially lead to improved efficacy and/or safety. We are pleased with Biogen’s decision to license ATV:Abeta and we are hopeful this will foster the development of next-generation anti-Abeta therapeutics."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNLI:
- Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
- Denali Therapeutics to present DNL343 Phase 1b data at AAN annual meeting
- Denali Therapeutics price target lowered to $32 from $36 at Stifel
- Denali Therapeutics price target lowered to $70 from $85 at Oppenheimer
- Denali Therapeutics price target lowered to $50 from $80 at Evercore ISI
